- Home
- OPK vs XERS Comparison
OPK vs XERS Comparison
Compare OPK & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- XERS
- Stock Information
- Founded
- OPK 2007
- XERS 2005
- Country
- OPK United States
- XERS United States
- Employees
- OPK N/A
- XERS N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- XERS Health Care
- Exchange
- OPK Nasdaq
- XERS Nasdaq
- Market Cap
- OPK 1.1B
- XERS 1.3B
- IPO Year
- OPK 1995
- XERS 2018
- Fundamental
- Price
- OPK $1.31
- XERS $7.00
- Analyst Decision
- OPK Buy
- XERS Strong Buy
- Analyst Count
- OPK 5
- XERS 7
- Target Price
- OPK $2.28
- XERS $10.00
- AVG Volume (30 Days)
- OPK 2.7M
- XERS 3.0M
- Earning Date
- OPK 10-29-2025
- XERS 11-06-2025
- Dividend Yield
- OPK N/A
- XERS N/A
- EPS Growth
- OPK N/A
- XERS N/A
- EPS
- OPK N/A
- XERS N/A
- Revenue
- OPK $642,067,000.00
- XERS $266,137,000.00
- Revenue This Year
- OPK N/A
- XERS $43.89
- Revenue Next Year
- OPK N/A
- XERS $20.40
- P/E Ratio
- OPK N/A
- XERS N/A
- Revenue Growth
- OPK N/A
- XERS 42.05
- 52 Week Low
- OPK $1.11
- XERS $3.02
- 52 Week High
- OPK $2.04
- XERS $10.08
- Technical
- Relative Strength Index (RSI)
- OPK 41.15
- XERS 33.91
- Support Level
- OPK $1.24
- XERS $6.71
- Resistance Level
- OPK $1.35
- XERS $7.27
- Average True Range (ATR)
- OPK 0.06
- XERS 0.51
- MACD
- OPK 0.00
- XERS -0.15
- Stochastic Oscillator
- OPK 51.35
- XERS 9.20
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).